FDA Approves B+L and Clearside Biomedical Drug for Treatment of Macular Edema Associated With Uveitis

LAVAL, QC and ALPHARETTA, Ga.—Bausch + Lomb, a global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) and Clearside Biomedical, Inc. (Nasdaq: CLSD) announced Monday that the U.S. Food and Drug Administration (FDA) has approved the drug Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation. "With this FDA approval, Xipere is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis," said Joseph C. Papa, chairman and CEO, Bausch Health.

Time Is Running Out—Cast Your Votes By Nov. 1 for Jobson's 2021 EyeVote Readers' Choice Awards

NEW YORK—Vision Monday and 20/20 Magazine are teaming up for the 13th annual EyeVote Readers' Choice Awards to identify the optical industry’s favorite products and companies this year.

New Ideas to Elevate the Patient Experience

NEW YORK—Digital technologies and access to business of all types, and health care in particular, have been on the rise for the past 18 months as the pandemic has transformed people’s work and personal lives. As a result, patient receptivity to digital tools, which can make their interactions with business more convenient and streamlined, have gained a lot of traction.

Reengineering and Renovation

The term “work in progress” accurately defines most prescription optical laboratories. No matter how smoothly a lab may be running, there’s always something that needs updating or replacing, whether it’s adding a single piece of equipment, reengineering an entire production line or even building a whole facility. It’s an endless cycle of invention and reinvention, and labs must learn to adjust to it while continuing to service customers, a challenge which can be daunting for any business.

VM Summit Panel: How Do New Remote Monitoring Tech and Wearables Extend ECP Relationships and Promote Healthy Outcomes?

NEW YORK—Escalated by the pandemic, consumers and patients are demonstrating their openness to using new technologies to redefine their own sense of wellness and take care of their own health. This is furthering the advent of new remote monitoring systems and wearables which are directly involving the patient in managing care with their doctors. Experts discussed these "Remote Possibilities" during VM's virtual Leadership Summit last week. They talked about how these technology developments can actually strengthen provider relationships with patients and provide healthier outcomes, too.